TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company…
Split Becomes Effective Monday, November 11, 2024Shareholder- and Board-Approved Action Reduces Shares Outstanding to 313,235 from 31 Million, Ensures Continued…
Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product…
WEDEL, Germany, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Testing new substances in animals is a regulatory cornerstone of drug development.…
MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial…
Conference Call Scheduled for Thursday, November 14, 2024 at 9:00 AM ETPORTLAND, Maine, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ImmuCell…
Partnerships will employ Vaccinex’s ActivMAb® platform for viral display of complex antigens to enable antibody discoveryROCHESTER, N.Y., Nov. 07, 2024…
Financials for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 will be released on Thursday, November 14,…
For the quarter ended September 30, 2024: Total Revenue of $2.4 billion, a 68% increase year-over-year Medical Loss Ratio of…
SHENZHEN, China, Nov. 7, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and…